Spotlight on Research 2016

December 2016

Engineered T Cells Alleviate Autoimmune Skin Disease in Mice

A new study, funded in part by the NIHís National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), has shown that engineered T cells can destroy antibody-producing cells that underlie a rare autoimmune disorder of the skin. The findings, which appeared in the journal Science, offer a new strategy for treating the disease, pemphigus vulgaris (PV), and possibly certain other autoimmune conditions as well.

PV occurs when the immune system, which normally protects the body, attacks normal proteins that link cells to one another in the skinís outer layer. Without these tethers, the cells separate, resulting in chronic blistering of the skin and mucous membranes. PV is treated with medicines that broadly suppress immune system functions, but these therapies can bring heightened susceptibility to infections and cancer. To avoid these side-effects, scientists need to develop new medicines that target only the part of the immune system that causes disease, while leaving the rest intact.

Microscope image of mucous membrane showing antibodies in red.

Disease-causing antibody (red) levels are lessened by treatment with engineered T cells [left hand panel]
compared to controls [right hand panel] in mucous membrane samples taken from mice with a form of pemphigus
vulgaris. Credit: Aimee S. Payne, M.D., Ph.D., and Michael C. Milone, M.D., Ph.D., University of Pennsylvania
School of Medicine.

Taking a step toward this goal, researchers led by Aimee S. Payne, M.D., Ph.D., and Michael C. Milone, M.D., Ph.D., of the University of Pennsylvania School of Medicine, borrowed from a strategy for treating cancer that was first described in the 1980s. The anti-cancer approach, which has shown promise in combating certain leukemias and lymphomas, involves reprogramming immune cells called killer T cells to destroy malignant cells, while passing over normal, healthy cells.

Earlier work on PV showed that the disease occurs when immune cells called B cells generate antibodies that target an adhesion protein in skin called desmoglein (Dsg3). Setting their sights on these B cells, Dr. Payneís and Dr. Miloneís teams engineered killer T cells that recognize and destroy them. Killer T cells function through surface receptors, which, upon recognizing specific proteins on other cells—usually virus-infected or tumor cells—transmit a signal to the T cellís interior. This signal triggers the release of molecules called cytokines that bring on the destruction of the potentially dangerous cells.

In order to single out the disease-causing B cells, the researchers engineered T cells to make an artificial version of the receptor that includes a segment of the Dsg3 protein. They theorized that the Dsg3 fragment would serve as a decoy, luring in the B cells and setting off the signal that unleashes the T cellsí destructive attack.

After testing several variants of the T cell receptor construct, the researchers succeeded in creating engineered T cells that efficiently destroyed cultured anti-Dsg3 antibody-producing B cells, including those obtained from PV patients. In addition, the reprogrammed T cells proved effective in treating PV in mice, preventing blistering and other signs of autoimmunity, with no evidence of side effects.

"The ability to specifically target cells that cause autoimmunity while sparing the rest of the immune system has long been a goal among investigators who study autoimmune diseases," said Dr. Payne. "Our work provides a proof of concept for an approach that could serve as the basis for the development of new medicines with fewer side effects for treating PV, as well as other autoimmune conditions."

In the future, Dr. Payne and Dr. Milone aim to test their approach on other types of autoimmune diseases, as well as on the immune rejection that can occur following organ transplant surgery.

This work was supported by the NIHís NIAMS (R01-AR057001, R01-AR068288, T32-AR007465, F31-AR066456, R01-AR055309 and P30-AR057217), National Cancer Institute (T32-CA009140) and National Heart, Lung, and Blood Institute (K12-HL087064). Other support came from the Penn Institute for Immunology, a Dermatology Foundation Charles and Daneen Stiefel Scholar Award, the Deutsche Forschungsgemeinschaft and the Italian Ministry of Health.

Kirstie Saltsman, Ph.D.

# # #

Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS. Science. 2016 Jul 8;353(6295):179-84. doi: 10.1126/science.aaf6756. PMID: 27365313

The mission of the NIAMS, a part of the U.S. Department of Health and Human Services' National Institutes of Health, is to support research into the causes, treatment and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases. For more information about the NIAMS, call the information clearinghouse at (301) 495-4484 or (877) 22-NIAMS (free call) or visit the NIAMS website at http://www.niams.nih.gov.